Bruker BRKR Bsi Biospin — Goodwill Impairment
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bruker in its filing.
Tagged under the XBRL concept us-gaap:GoodwillImpairmentLoss.
The source filing: Bruker’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:24 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335226
During the three months ended June 30, 2026, the Company reduced its forecasted revenue and cash flows for the CST (formerly Automation) reporting unit. As a result, the Company performed a goodwill impairment test for the CST reporting unit. During the three and six months ended June 30, 2026, the Company recorded a goodwill impairment charge of $98.4 million in the unaudited condensed consolidated statements of operations within the BSI BioSpin segment, which represented the remaining goodwill balance of the CST reporting unit.
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Bruker's bsi biospin — goodwill impairment?
- Bruker (BRKR) reported bsi biospin — goodwill impairment of $98.4M in Q2 2026.
- What does bsi biospin — goodwill impairment mean?
- This metric quantifies the reduction in the carrying value of goodwill within the BioSpin segment when the recorded amount exceeds its implied fair value. It serves as a critical indicator that the expected economic benefits from past acquisitions in this segment have diminished. A significant impairment charge often signals operational challenges or a decline in the long-term outlook for the segment's specific product lines.
Ask your AI about Bruker's bsi biospin — goodwill impairment.
Connect your AI assistant and compare segments, right in your chat.
